Oxford Cannabinoid Technologies work on treatment for chronic, painful disease Trigeminal Neuralgia

Oxford Cannabinoid Technologies Holdings PLC (LSE:OCTP) Valentino Parravicini, Chief Scientific, Officer joins Proactive London's Katie Pilbeam to talk about their treatment for trigeminal neuralgia (TN).

This is a rare and chronic pain condition which in most cases is excruciatingly painful and in the very worst cases patients even contemplate suicide.

The aim is to secure orphan designation for the approach, which is conferred where there is an unmet medical need and the designation could shorten the timeline to market.
Be the first to comment